Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Cost effectiveness of epidural steroid injections to manage chronic lower back pain.

Whynes DK, McCahon RA, Ravenscroft A, Hardman J.

BMC Anesthesiol. 2012 Sep 27;12:26. doi: 10.1186/1471-2253-12-26.

2.

Cost-effectiveness of steroid (methylprednisolone) injections versus anaesthetic alone for the treatment of Morton's neuroma: economic evaluation alongside a randomised controlled trial (MortISE trial).

Edwards RT, Yeo ST, Russell D, Thomson CE, Beggs I, Gibson JN, McMillan D, Martin DJ, Russell IT.

J Foot Ankle Res. 2015 Feb 25;8:6. doi: 10.1186/s13047-015-0064-y. eCollection 2015.

3.

BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L; BoTULS investigators.

Health Technol Assess. 2010 May;14(26):1-113, iii-iv. doi: 10.3310/hta14260.

4.

Cost-effectiveness and safety of epidural steroids in the management of sciatica.

Price C, Arden N, Coglan L, Rogers P.

Health Technol Assess. 2005 Aug;9(33):1-58, iii.

5.

Cost per quality-adjusted life year gained of laminectomy and extension of instrumented fusion for adjacent-segment disease: defining the value of surgical intervention.

Adogwa O, Parker SL, Shau DN, Mendenhall SK, Devin CJ, Cheng JS, McGirt MJ.

J Neurosurg Spine. 2012 Feb;16(2):141-6. doi: 10.3171/2011.9.SPINE11419. Epub 2011 Nov 4.

PMID:
22054637
6.

Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain.

Thomas KJ, MacPherson H, Ratcliffe J, Thorpe L, Brazier J, Campbell M, Fitter M, Roman M, Walters S, Nicholl JP.

Health Technol Assess. 2005 Aug;9(32):iii-iv, ix-x, 1-109.

7.

Cost-effectiveness of multilevel hemilaminectomy for lumbar stenosis-associated radiculopathy.

Parker SL, Fulchiero EC, Davis BJ, Adogwa O, Aaronson OS, Cheng JS, Devin CJ, McGirt MJ.

Spine J. 2011 Aug;11(8):705-11. doi: 10.1016/j.spinee.2011.04.024. Epub 2011 Jun 8.

PMID:
21641874
8.

Cost-effectiveness of transforaminal lumbar interbody fusion for Grade I degenerative spondylolisthesis.

Adogwa O, Parker SL, Davis BJ, Aaronson O, Devin C, Cheng JS, McGirt MJ.

J Neurosurg Spine. 2011 Aug;15(2):138-43. doi: 10.3171/2011.3.SPINE10562. Epub 2011 May 6. Erratum in: J Neurosurg Spine. 2011 Aug;15(2):211.

PMID:
21529203
9.

Cost per quality-adjusted life year gained of revision neural decompression and instrumented fusion for same-level recurrent lumbar stenosis: defining the value of surgical intervention.

Adogwa O, Parker SL, Shau DN, Mendenhall SK, Aaronson O, Cheng JS, Devin CJ, McGirt MJ.

J Neurosurg Spine. 2012 Feb;16(2):135-40. doi: 10.3171/2011.9.SPINE11308. Epub 2011 Nov 4.

PMID:
22054639
10.
11.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
12.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

13.

Cost-effectiveness of minimally invasive versus open transforaminal lumbar interbody fusion for degenerative spondylolisthesis associated low-back and leg pain over two years.

Parker SL, Adogwa O, Bydon A, Cheng J, McGirt MJ.

World Neurosurg. 2012 Jul;78(1-2):178-84. doi: 10.1016/j.wneu.2011.09.013. Epub 2011 Nov 7.

PMID:
22120269
14.

Management of frozen shoulder: a systematic review and cost-effectiveness analysis.

Maund E, Craig D, Suekarran S, Neilson A, Wright K, Brealey S, Dennis L, Goodchild L, Hanchard N, Rangan A, Richardson G, Robertson J, McDaid C.

Health Technol Assess. 2012;16(11):1-264. doi: 10.3310/hta16110. Review.

15.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

16.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
17.

Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.

Obradovic M, Ikenberg R, Hertel N, Antoñanzas F, Gálvez R, Liedgens H.

Clin Ther. 2012 Apr;34(4):926-43. doi: 10.1016/j.clinthera.2012.02.011. Epub 2012 Mar 13.

PMID:
22417717
18.

Cost-utility analysis of osteopathy in primary care: results from a pragmatic randomized controlled trial.

Williams NH, Edwards RT, Linck P, Muntz R, Hibbs R, Wilkinson C, Russell I, Russell D, Hounsome B.

Fam Pract. 2004 Dec;21(6):643-50. Epub 2004 Nov 5.

19.

A cost-effectiveness analysis of an in-hospital clinical pharmacist service.

Wallerstedt SM, Bladh L, Ramsberg J.

BMJ Open. 2012 Jan 5;2:e000329. doi: 10.1136/bmjopen-2011-000329. Print 2012.

20.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk